Aurobindo 旗下 Eugia 因药瓶可能含玻璃颗粒召回一批盐酸万古霉素注射剂
Aurobindo unit Eugia recalls antibiotic lot, citing glass particle concerns
Aurobindo 旗下 Eugia 自愿召回一批盐酸万古霉素注射剂(批号 3VM26026A),原因是药瓶中可能含有玻璃颗粒。该批产品为 30ml、10 瓶装,有效期至 2028 年 7 月,于今年 9 月 2 日至 15 日在美国全国分销;公司 11 月 6 日刊登在 FDA 产品安全网站上的函件称,尚未收到与本次召回相关的不良反应报告。

Aurobindo unit Eugio issued a voluntary recall for one lot of the antibiotic vancomycin hydrochloride for injection, citing the possible presence of glass particles in vials. (Stock photo/Getty Images)
Eugia, a unit of Aurobindo, has issued a voluntary recallfor one lot of the injectable antibiotic vancomycin hydrochloride, citing the possible presence of glass particles in the vials.
The recalled product, which is typically used to treat septicemia, infective endocarditis, skin infections and lower respiratory tract infections, is packaged in 30ml, 10-vial packs with the lot number 3VM26026A and an expiration date of July 2028.

The product was distributed nationwide in the U.S. between Sept. 2 and Sept. 15 of this year.
The company warned in a letter posted to the FDA’s product safety website that use of the recalled lot could cause “blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death.”
As of the posting, dated Nov. 6, the company said it hadn’t received any reports of adverse effects related to the recall.
In August, Eugia’s facility in Hyderabad was hit with a warning letter that was related to an inspection earlier this year that resulted in a Form 483. Prior to that rebuke, the company had received four FDA Form 483s across various sites in its network since late 2023.
Meanwhile, multiple other drugmakers producing injectable medicines have struggled with particulate contamination issues this year, leading to recalls from the likes of Par Health, B. Braun and Baxter, to name a few examples.
来源:Fierce Pharma Manufacturing · fiercepharma.com